Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy

Bone

Volumn 18, Issue 3 SUPPL., 1996, Pages S197-S201

  Riggs, B Lawrence ^a   Melton III, L J ^a   O'Fallon, W M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antiresorptive regimens; Estrogen; Fluoride; Formation stimulating regimens

Indexed keywords

ALENDRONIC ACID; CALCITRIOL; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE;

BONE MASS; BONE TURNOVER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; TRANSDERMAL DRUG ADMINISTRATION; VERTEBRA FRACTURE;

BONE DENSITY; BONE RESORPTION; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIALS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FLUORIDES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; SPINE;

EID: 0029923080     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/8756-3282(95)00502-1     Document Type: Article

References (26)

1. Dambacher, M. A., Ittner, J., and Ruegsegger, P. Long-term fluoride therapy of postmenopausal osteoporosis. Bone 7:199-205; 1986.
2. Delmas, P. D., Stenner, D., Wahner, H. W., Mann, K. G., and Riggs, B. L. Increase in serum bone gamma-carboxyglutamic acid protein with aging in women: Implications for the mechanism of age-related bone loss. J Clin Invest 71:1316-1321; 1983.
3. Eastell, R., Robins, S. P., Colwell, T., Assiri, A. M. A., Riggs, B. L., and Russell, R. G. G. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteopor Int 3:255-260; 1993.
4. Einhorn, T. A. Bone strength: The bottom line. Calcif Tissue Int 51:333-339; 1992.
5. Eriksen, E. F., Hodgson, S. F., Eastell, R., O'Fallon, W. F., and Riggs, B. L. Trabecular bone formation and resorption rates in type I (postmenopausal) osteoporosis. J Bone Miner Res 3:S203; 1988.
6. Gallagher, J. C., Riggs, B. L., Recker, R. R., and Goldgar, D. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 191:287-292; 1989.
7. Garnero, P., Hauser, E., Chapuy, M. C., Marcelli, C., Grandjean, H., Muller, C., Cormier, C., Breard, G., Meunier, P. J., and Delmas, P.D. Can markers (MK) of bone turnover predict hip fractures (FX) in elderly women? The EPIDOS study. HJ Bone Miner Res 10(suppl 1):S140; 1995 (abstract No. 6).
8. Johnston. C. C., Slemenda, C. W., and Melton, L. J. Clinical use of bone densitometry. N Engl J Med 324:1105-1109; 1991.
9. Kleerekoper, M., Peterson, E. L., Nelson, D. A., Phillips, E., Schork, M. A., Tilley, B. C., and Parfitt, A. M. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1:155-161; 1991.
10. Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., and Riggs, B. L. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:1-9; 1992.
11. Mamelle, N., Dusan, R., Martin, J. L., Prost, A., Meunier, P. J., Guillaume, M., Gaucher, A., and Zeigler, G. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 2:361-365; 1988.
12. Pak, C. Y. C., Sakhaee, K., Piziak, V., Peterson, R. D., Breslau, N. A., Boyd, P., Poindexter, J. R., Herzog, J., Heard-Sakhaee, A., Haynes, S., Adams-Huet, B., and Reisch, J. S. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. Ann Intern Med 120:625-632; 1994.
13. Parfitt, A. M., Mathews, C. H. E., Villaneuva, A. R., Kleerekoper, M., Frame, B., and Rao, D. S. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. J Clin Invest 72:1396-1409; 1983.
14. Recker, R. R., Karpf, D. B., Quan. H., Devogelaer, C., Leite, M. O., Favus, M. J., Minne, H. W., Capizzi, T., Lombardi, A., Shah, R., Peverly, C., Hirsch, L. J., and Santora, A. C. Three-year treatment of osteoporosis with alendronate: Effect on vertebral fracture incidence. Proceedings of the 77th Annual Meeting of the Endocrine Society, 1995.
15. Riggs, B. L. Treatment of osteoporosis with sodium fluoride: An appraisal. Peck, W. A., Ed. Bone and Mineral Research, Annual 2: A Yearly Survey of Developments in the Field of Bone and Mineral. New York, NY: Elsevier; 1984; 366-393.
16. Riggs, B. L., Hodgson, S. F., O'Fallon, W. M., Chao, E. Y. S., Wahner, H. W., Muhs, J. M., Cedel, S. L., and Melton, L. J., III. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809; 1990.
17. Riggs, B. L. and Melton, L. J. The prevention and treatment of osteoporosis. N Engl J Med 327:620-627; 1992.
18. Riggs, B. L., Melton, L. J., III, and O'Fallon, W. M. Toward optimal therapy of established osteoporosis: Evidence that antiresorptive and formation-stimulating regimens decrease vertebral fracture rate by independent mechanisms. Christiansen, C. and Riis, B., Eds. Osteoporosis 1993. Rodovre, Denmark: Osteopress ApS; 1993; 13-15.
19. Riggs, B. L., O'Fallon, W. M., Lane, A., Hodgson, S. F., Wahner, H. W., Muhs, J., Chao, E., and Melton, L. J. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: Extended observations and additional analysis. J Bone Miner Res 9:26.1-275; 1994.
20. Riggs, B. L., Seeman, E., Hodgson, S. F., Taves, D. R., and O'Fallon, W. M. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: Comparison with conventional therapy. N Engl J Med 306:446-450; 1982.
21. Riggs, B. L., Wahner, H. W., Seeman, E., Offord, K. P., Dunn, W. L., Mazess, R. B., Johnson, K. A., and Melton, L. J., III. Changes in bone mineral density of the proximal femur and spine with aging: Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest 70:716-723; 1982.
22. SAS/GRAPH Software, Reference 2, Version 6, 1st ed. Cary, NC: SAS Institute; 1990.
23. Sogaard, C. H., Mosekilde, L., Richards, A., and Mosekilde, L. Marked decrease in trabecular bone quality after five years of sodium fluoride therapy -Assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients. Bone 15:393-399; 1994.
24. Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., and Sorensen, O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271; 1990.
25. Tilyard, M. W., Spears, G. F. S., Thomson, J., and Dovey, S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357-362; 1992.
26. Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., Yanover, M. J., Mysiw, W. J., Kohse, L., Rao, M. B., Steiger, P., Richmond, B., and Chesnut, C. H. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79; 1990.